Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of XZP-6019 in Healthy Subjects
NCT05063968Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XZP-6019 in non-alcoholic fatty liver disease (NAFLD) (6 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Concentration at 72 hours and 6 more. Status: unknown.
02
Drugs
XZP-6019
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05063968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063968.